Treatment of Methicillin-Resistant Streptococcus aureus With a Vancomycin Minimum Inhibitory Concentration of 2 mcg/mL

Kettle, Jacob K.; Grace, Jason W.; Schaefer, Spencer; Desai, Arundhati
May 2010
Hospital Pharmacy;May2010, Vol. 45 Issue 5, p375
Academic Journal
Background: Vancomycin has been considered the standard of therapy for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) for decades. The aims of this study were to describe the clinical outcomes of patients with infectious caused by MRSA with a vancomycin minimum inhibitory concentration (MIC) of 2 mcg/mL and determine whether achievement of a high vancomycin trough concentration affected outcomes. Methods: A retrospective analysis was conducted on data front a single medical center from 2003 through 2007. The study included patients with a culture positive for MRSA with a vancomycin MIC of 2 mcg/mL who received vancomycin therapy. Treatment groups were determined by weighted average vancomycin trough concentration. Subjects were assigned to either the conventional (less than 15 mcg/mL) or high (15 mcg/ml, or higher) trough group. Outcome measures included attainment of clinical cure, all-cause mortality, and occurrence of nephrotoxicity. Results: Of the 79 patients included in the study, 50 (63.3%) attained clinical cure. Rate of clinical cure was similar between the conventional and high trough groups (64.7% vs 60.7%, P = 0.7). Treatment arms were similar in regard to all-cause mortality and other secondary endpoints. Patients demonstrating clinical response at 72 hours were significantly more likely to progress to clinical cure than those continuing to show signs of refection (77.g% vs 32.5, P < 0.001). Conclusions: Use of vancomycin for the treatment of MRSA with a vancomycin MIC of 2 mcg/mL resulted in a low rate of clinical cure. Data from this study suggest that achieving higher yahoo mycin trough concentrations is not a sufficient strategy for enhancing efficacy in these challenging infectious.


Related Articles

  • The Efficacy and Safety of Arbekacin and Vancomycin for the Treatment in Skin and Soft Tissue MRSA Infection: Preliminary Study. Ji-Hee Hwang; Ju-Hyung Lee; Mi-Kyoung Moon; Ju-Sin Kim; Kyoung-Suk Won; Chang-Seop Lee // Infection & Chemotherapy;Mar2013, Vol. 45 Issue 1, p62 

    Background: Methicillin-resistant Staphylococcus aureus (MRSA) has become a one of the most important causes of nosocomial infections, and use of vancomycin for the treatment of MRSA infection has increased. Unfortunately, vancomycin-resistant enterococcus have been reported, as well as...

  • Which antibiotic for hospital acquired pneumonia caused by MRSA? Muscedere, John // BMJ: British Medical Journal;3/8/2014, Vol. 348 Issue 7948, p10 

    The author discusses whether newer antibiotics to cure hospital-acquired pneumonia caused by the bacterium Methicillin-resistant Staphylococcus aureus (MRSA) are more effective than the conventional vancomycin. A brief comparison between several drugs which include daptomycin, ceftaroline, and...

  • Treating Patients With the Best Drugs. Parra-Ruiz, J. // Clinical Infectious Diseases;Oct2013, Vol. 57 Issue 8, p1218 

    A letter to the editor in response to the article "Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?" by S.J. van Hal and V.G. Fowler in a 2013 issue is presented.

  • Pharmacoeconomic advantages of oral minocycline for the therapy of methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs). Cunha, B. // European Journal of Clinical Microbiology & Infectious Diseases;Oct2014, Vol. 33 Issue 10, p1869 

    A letter to the editor is presented in response to the article "Economic Evaluation of Treatment for MRSA Complication Skin and Soft Tissue Infections in Glasgow Hospitals," by R. A. Seaton et al. in a 2014 issue of the "European Journal of Clinical Microbiology & Infectious Diseases."

  • Safety and Efficacy of Daptomycin in the Treatment of Gram-Positive Pathogens. Kelesidis, Theodoros // Clinical Medicine Insights: Therapeutics;2011, Issue 3, p403 

    Daptomycin is an antibacterial agent with activity against Gram-positive organisms and is a reliable option for the treatment of invasive Gram-positive infections. Daptomycin has been approved for the treatment of complicated skin and skin-structure infections and bacteremia including...

  • Antibiotic Treatment Against Methicillin-Resistant Staphylococcus aureus Hospital- and Ventilator-acquired Pneumonia: A Step Forward but the Battle Continues. Torres, Antoni // Clinical Infectious Diseases;3/1/2012, Vol. 54 Issue 5, p630 

    The author reflects on various treatment approaches for hospital-acquired and ventilator-acquired pneumonia caused by Methicillin-resistant Staphylococcus aureus (MRSA) . He discusses the randomized controlled trials performed to compare the efficacy and effectiveness of linezolid and vancomycin...

  • Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. Bowker, Karen E.; Noel, Alan R.; MacGowan, Alasdair P. // Journal of Antimicrobial Chemotherapy (JAC);Nov2009, Vol. 64 Issue 5, p1044 

    Objectives: To compare the antibacterial effects (ABEs) of the free (f) drugs daptomycin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA), using high and low inocula in a pharmacokinetic in vitro model. To determine...

  • Understanding the appropriate and effective use of vancomycin. duPreez, Elizabeth // JAAPA: Journal of the American Academy of Physician Assistants (;Nov2011, Vol. 24 Issue 11, p18 

    The article focuses on the effective utilization of vancomycin to treat infections with antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). It notes that the drug must be dosed early, with a loading dose given for speedy achievement of direct concentrations....

  • Reply to Parra-Ruiz. van Hal, Sebastiaan J.; Fowler, Vance G. // Clinical Infectious Diseases;Oct2013, Vol. 57 Issue 8, p1219 

    A reply to the letter to the editor by the authors about their article "Is it time to replace vancomycin in the treatment of methicillin-reistant Staphylococcus aureus infections?" in the 2013 issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics